Non-homogeneous systems for the resolution of enantiomeric mixtures
    4.
    发明申请
    Non-homogeneous systems for the resolution of enantiomeric mixtures 有权
    用于解析对映异构体混合物的非均相体系

    公开(公告)号:US20070004024A1

    公开(公告)日:2007-01-04

    申请号:US11318650

    申请日:2005-12-27

    IPC分类号: C12P41/00

    CPC分类号: C12P17/16 C12P41/001

    摘要: The present invention relates to a process for the biocatalyst-mediated enantioselective conversion of enantiomeric mixtures of hydrophobic esters uing a biphasic solvent system. More particularly, the present invention relates to the enzyme-mediated enantioselective synthesis of anti-viral compounds, such as 2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane (FTC) and its analogues, in a non-homogenous reaction system.

    摘要翻译: 本发明涉及一种生物催化剂介导的对映异构体转化与双相溶剂系统的疏水酯的对映体混合物的方法。 更具体地,本发明涉及抗病毒化合物如2-羟甲基-5-(5-氟胞嘧啶-1-基)-1,3-氧硫杂环戊烷(FTC)及其类似物的酶介导的对映选择性合成, 在非均匀的反应体系中。

    Compounds, compositions and methods for the treatment of viral infections and other medical disorders
    5.
    发明申请
    Compounds, compositions and methods for the treatment of viral infections and other medical disorders 审中-公开
    用于治疗病毒感染和其他医学疾病的化合物,组合物和方法

    公开(公告)号:US20070003608A1

    公开(公告)日:2007-01-04

    申请号:US11402159

    申请日:2006-04-10

    IPC分类号: A61K31/675 A61K9/127

    摘要: The present application provides methods and compositions for improving the bioavailability of a lipid-containing antiviral compound, and in particular, an antiviral lipid-containing compound. In one embodiment, pharmaceutically acceptable compositions are provided that include an antiviral lipid-containing compound, or salt, ester, or prodrug thereof and one or more bioavailability enhancing compounds, such as inhibitors of cytochrome P450 enzymes.

    摘要翻译: 本申请提供了用于改善含脂质抗病毒化合物,特别是抗病毒含脂化合物的生物利用度的方法和组合物。 在一个实施方案中,提供药学上可接受的组合物,其包含抗病毒含脂质化合物或其盐,酯或前药以及一种或多种生物利用度增强化合物,例如细胞色素P450酶的抑制剂。

    Methods to manufacture 1,3-dioxolane nucleosides
    6.
    发明申请
    Methods to manufacture 1,3-dioxolane nucleosides 有权
    1,3-二氧戊环核苷的制备方法

    公开(公告)号:US20060036092A1

    公开(公告)日:2006-02-16

    申请号:US11051287

    申请日:2005-02-03

    IPC分类号: C07D473/10 C07D407/04

    摘要: This application provides a process for preparing enantiomerically pure β-D-dioxolane nucleosides. In particular, a new synthesis of (−)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure β-D- or β-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected β-D- or P-L-1,3-dioxolane nucleoside.

    摘要翻译: 该应用提供了制备对映体纯的β-D二氧戊环核苷的方法。 特别地,描述了适用于大规模开发的( - ) - DAPD的新合成。 在一个实施方案中,本发明提供了制备基本上纯的β-D-或β-L-1,3-二氧戊环核苷的方法,其包括a)制备或获得酯化的2,2-二烷氧基乙醇; b)用乙醇酸环化酯化的2,2-二烷氧基乙醇得到1,3-二氧戊环内酯; c)拆分1,3-二氧戊环内酯以获得基本上纯的D-或L-内酯; d)选择性还原和活化D-或L-手性内酯,得到基本上纯的D-或L-1,3-二氧戊环; e)将D-或L-1,3-二氧戊环与活化和/或受保护的嘌呤或嘧啶碱基偶联; 和f)任选地纯化核苷以获得基本上纯的保护的β-D-或P-L-1,3-二氧戊环核苷。

    Compounds, compositions and methods for the treatment of poxvirus infections
    8.
    发明申请
    Compounds, compositions and methods for the treatment of poxvirus infections 有权
    用于治疗痘病毒感染的化合物,组合物和方法

    公开(公告)号:US20070003516A1

    公开(公告)日:2007-01-04

    申请号:US11401805

    申请日:2006-04-10

    摘要: The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or a salt, ester, or prodrug thereof in combination or alternation with at least a second anti-poxvirus agent. The second anti-poxvirus agent is, for example, a biologic, such as a pegylated interferon.

    摘要翻译: 本申请提供了用于治疗痘病毒感染(例如正痘病毒感染)的抗病毒化合物联合治疗的方法和组合物。 在一个实施方案中,提供了治疗痘病毒感染的方法,其包括向有需要的宿主施用西多福韦,环西非多韦或其盐,酯或前药与至少第二种抗痘病毒剂组合或替代 。 第二种抗痘病毒剂是例如生物制剂,例如聚乙二醇化干扰素。